Returns Chart

Key Stats

Customize
Expense Ratio Total Assets Under Management Dividend Yield Turnover Ratio
1.85% 2.462B 0.00% 45.00%
1 Year Fund Level Flows 1 Year Total Returns (Daily) Annualized All Time Total Returns (Daily) Max Drawdown (All)
-124.15M 31.20% Upgrade Upgrade

Basic Info

Investment Strategy
The investment seeks long-term capital appreciation. The fund seeks investments whose prices will increase over time. It normally invests at least 80% of its investable assets in equity and equity-related securities of companies within the health sciences sector, such as pharmaceutical companies, biotechnology companies, medical device manufacturers, healthcare service providers and health maintenance organizations (HMOs) and other companies that derive at least 50% of their assets, revenues or profits from operations in the healthcare sector. The fund is non-diversified.
General
Security Type Mutual Fund
Oldest Share Symbol PHSZX
Equity Style Large Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Prospectus Objective Specialty - Health
Fund Owner Firm Name PGIM Funds (Prudential)
Prospectus Benchmark Index
S&P 1500 Health Care TR 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
David Chan 22.02 yrs
Debra Netschert 6.43 yrs
Daniel Matviyenko 0.54 yrs

Net Fund Flows Versus Category

View Net Fund Flows. Upgrade now.
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
 
80.00B
60.00B
40.00B
20.00B
0
-20.00B
1 Month
% Rank: --
-- Category Low
-- Category High
1 Year
% Rank: 81
-124.15M
-4.645B Category Low
7.623B Category High
3 Months
% Rank: --
-- Category Low
-- Category High
3 Years
% Rank: --
-- Category Low
-- Category High
6 Months
% Rank: --
-- Category Low
-- Category High
5 Years
% Rank: --
-- Category Low
-- Category High
YTD
% Rank: --
-- Category Low
-- Category High
10 Years
% Rank: --
-- Category Low
-- Category High
As of June 30, 2021

Performance Versus Category

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (NAV)
--
--
--
--
--
--
--
--
Category Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Cat (NAV)
--
--
--
--
--
--
--
--
As of July 22, 2021. Returns for periods of 1 year and above are annualized.

Annual Total Returns Versus Peers

Edit comparables
Name
2014
2015
2016
2017
2018
2019
2020
YTD
34.48%
4.31%
-15.26%
30.11%
-4.34%
17.45%
40.24%
9.42%
4.94%
-0.87%
7.51%
22.40%
-8.71%
27.67%
15.90%
14.20%
19.44%
2.22%
-12.35%
14.57%
-0.27%
30.99%
13.58%
6.79%
--
--
--
--
--
--
36.05%
5.61%
21.10%
1.58%
-4.05%
36.11%
4.96%
21.09%
30.02%
8.16%
31.24%
5.15%
-10.98%
23.12%
6.55%
26.96%
20.16%
9.27%
As of July 22, 2021.

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (7-22-21) 0.00%
30-Day SEC Yield --
7-Day SEC Yield (7-16-21) Upgrade
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio 24.65
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of June 30, 2021

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of June 30, 2021

Asset Allocation

As of June 30, 2021.
Type % Net % Long % Short
Cash -0.03% Upgrade Upgrade
Stock 98.92% Upgrade Upgrade
Bond 0.00% Upgrade Upgrade
Convertible 0.00% Upgrade Upgrade
Preferred 0.03% Upgrade Upgrade
Other 1.09% Upgrade Upgrade

Top 10 Holdings

Name % Weight Price % Change
UnitedHealth Group Inc 6.87% 417.68 0.46%
Humana Inc 6.05% 471.34 1.65%
Eli Lilly and Co 4.93% 244.41 2.48%
Danaher Corp 3.34% 291.38 0.84%
Intellia Therapeutics Inc 3.34% 137.70 -6.88%
Apellis Pharmaceuticals Inc 3.21% 68.17 4.04%
DexCom Inc 3.02% 460.68 2.17%
WuXi Biologics (Cayman) Inc Registered Shs Unitary 144A/Reg S
2.77% -- --
Zai Lab Ltd ADR Repr 1 Shs 2.59% 150.02 -6.82%
Intuitive Surgical Inc 2.50% 976.14 0.23%

Fees & Availability

Fees
Actual 12B-1 Fee Upgrade
Actual Management Fee Upgrade
Administration Fee --
Performance Fee --
Switching Fee --
Transaction Fee --
Maximum Front Load --
Maximum Deferred Load Upgrade
Maximum Redemption Fee --
General Availability
Available for Insurance Product No
Available for Retirement Plan No
Available for RRSP No
Purchase Details
Open to New Investors Yes
Open to Existing Investors Yes
Minimum Initial Investment Upgrade
Minimum Subsequent Investment Upgrade

Basic Info

Investment Strategy
The investment seeks long-term capital appreciation. The fund seeks investments whose prices will increase over time. It normally invests at least 80% of its investable assets in equity and equity-related securities of companies within the health sciences sector, such as pharmaceutical companies, biotechnology companies, medical device manufacturers, healthcare service providers and health maintenance organizations (HMOs) and other companies that derive at least 50% of their assets, revenues or profits from operations in the healthcare sector. The fund is non-diversified.
General
Security Type Mutual Fund
Oldest Share Symbol PHSZX
Equity Style Large Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Prospectus Objective Specialty - Health
Fund Owner Firm Name PGIM Funds (Prudential)
Prospectus Benchmark Index
S&P 1500 Health Care TR 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
David Chan 22.02 yrs
Debra Netschert 6.43 yrs
Daniel Matviyenko 0.54 yrs

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (7-22-21) 0.00%
30-Day SEC Yield --
7-Day SEC Yield (7-16-21) Upgrade
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio 24.65
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of June 30, 2021

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of June 30, 2021

Fund Details

Key Dates
Inception Date 6/30/1999
Last Annual Report Date 11/30/2020
Last Prospectus Date 3/1/2021
Share Classes
PHLAX A
PHLQX Retirement
PHSZX Inst
PJHRX Retirement
Attributes
Enhanced Index Fund No
Index Fund No
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No